Psoriasis is a chronic inflammatory skin disease that may have an important negative impact on a patient's quality of life. Biological agents deeply changed the management of its moderate-to-severe forms. Interleukin-23 inhibitors represent the latest biologics class approved for the treatment of moderate to severe psoriasis. Particularly, tildrakizumab, the latest available anti-interleukin-23 on the Italian market, is a humanized monoclonal antibody specifically targeting the p19 subunit of IL-23.
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge / Ruggiero, Angelo; Camela, Elisa; Potestio, Luca; Fabbrocini, Gabriella; Megna, Matteo. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - (2022). [10.1080/14740338.2022.2160447]
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge
Angelo Ruggiero;Elisa Camela;Luca Potestio;Gabriella Fabbrocini;Matteo Megna
2022
Abstract
Psoriasis is a chronic inflammatory skin disease that may have an important negative impact on a patient's quality of life. Biological agents deeply changed the management of its moderate-to-severe forms. Interleukin-23 inhibitors represent the latest biologics class approved for the treatment of moderate to severe psoriasis. Particularly, tildrakizumab, the latest available anti-interleukin-23 on the Italian market, is a humanized monoclonal antibody specifically targeting the p19 subunit of IL-23.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
